Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Temozolomide,TMZ2020USA,2020,USA,MDV,350,62,45,55,26.5,32,85,0,15,30,40,15,60,25,10,5,20,35,45,12,5,3,7,4,0,75,60,N/A,N/A,Temozolomide,Temozolomide + Procarbazine,0,0,0,25,80,65,15,45,40,55,1
Temozolomide,TMZ2021EUR,2021,Germany,Claim Database,420,65,48,52,27.1,35,82,0,12,28,42,18,58,27,9,6,18,33,49,14,6,4,8,5,0,72,58,N/A,N/A,Temozolomide,Temozolomide + Bevacizumab,0,0,0,28,78,68,12,48,40,60,1
Temozolomide,TMZ2022ASIA,2022,Japan,MDV,280,68,42,58,25.8,28,88,0,18,32,38,12,62,23,11,4,22,37,41,10,4,2,6,3,0,78,62,N/A,N/A,Temozolomide,Temozolomide + Nimustine,0,0,0,22,82,62,18,42,40,58,1
